Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (34)

« Back to Publications

Combined crystallographic fragment screening and deep mutational scanning enable discovery of Zika virus NS2B-NS3 protease inhibitors.

Ni X. et al, (2025), Nat Commun, 16

Discovery of orally bioavailable Zika and West Nile Virus antiviral compounds targeting the NS2B-NS3 protease.

Kenton NT. et al, (2025)

Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor.

Griffen EJ. et al, (2025)

Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals.

Brun J. et al, (2025), Antiviral Res, 237

Identification and characterization of human KALRN mRNA and Kalirin protein isoforms.

Mould AW. et al, (2024), Cereb Cortex, 34

Enabling equitable and affordable access to novel therapeutics for pandemic preparedness and response via creative intellectual property agreements.

Griffen EJ. et al, (2024), Wellcome Open Res, 9

An Update on SARS-CoV-2 Clinical Trial Results-What We Can Learn for the Next Pandemic.

Arman BY. et al, (2023), Int J Mol Sci, 25

Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.

Boby ML. et al, (2023), Science, 382

Accelerating antiviral drug discovery: lessons from COVID-19.

von Delft A. et al, (2023), Nat Rev Drug Discov, 22, 585 - 603

Turning high-throughput structural biology into predictive inhibitor design.

Saar KL. et al, (2023), Proc Natl Acad Sci U S A, 120

Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP).

Smilde BJ. et al, (2022), BMC Musculoskelet Disord, 23

SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids.

Jansen J. et al, (2022), Cell Stem Cell, 29, 217 - 231.e8

Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia.

Mould AW. et al, (2022), CNS Drugs, 36, 1 - 16

An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor.

Zaidman D. et al, (2021), Cell Chem Biol, 28, 1795 - 1806.e5

A white-knuckle ride of open COVID drug discovery.

von Delft F. et al, (2021), Nature, 594, 330 - 332

Load More